tradmap

ESLA Earnings Estrella Immunopharma, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$36 -$18 $0 2023 2024 2025
EPS
Net income (annual)
-$13M -$7M $0 2021 2022 2023 2024 2025
Net income
Return on equity (annual)
-171% -23% 126% 0% 2021 2022 2023 2024 2025
ROE

Quarterly results

Diluted EPS (quarterly)
-$45 -$22 $0 Q4 '22 Q3 '23 Q1 '24 Q3 '24 Q2 '25 Q1 '26
EPS
Net income (quarterly)
-$6M -$3M $0 Q2 '23 Q4 '23 Q2 '24 Q1 '25 Q3 '25 Q1 '26
Net income
Return on equity (quarterly)
-452% -169% 115% 0% Q2 '23 Q4 '23 Q2 '24 Q1 '25 Q3 '25 Q1 '26
ROE

Reported EPS history

1–21 of 21
Q2 20262026-06-30-0.112026-08-1310-Q
Q1 20262026-03-31-0.052026-05-1810-Q
FY 20252025-12-31-0.352026-03-1810-K
Q3 20252025-09-30-0.342025-11-1210-Q
Q2 20262025-06-30-0.212026-08-1310-Q
Q1 20262025-03-31-0.062026-05-1810-Q
FY 20252024-12-31-0.122026-03-1810-K
Q3 20252024-09-30-0.222025-11-1210-Q
Q2 20252024-06-30-0.122025-08-1210-Q
Q1 20252024-03-31-0.012025-05-1410-Q
Q2 20232023-12-31-0.162024-02-1410-Q
Q1 20252023-09-30-1.782024-11-1410-Q
FY 20242023-06-30-36.352024-09-2710-K
Q3 20242023-03-31-39.952024-05-1510-Q
Q2 20232022-12-31-44.632024-02-1410-Q
Q1 20242022-09-30-34.332023-11-2010-Q
Q2 20222022-06-30-0.092022-08-0810-Q
Q1 20222022-03-31-0.022022-05-1610-Q
Q3 20222021-09-30-2.062022-11-1410-Q
Q2 20222021-06-300.002022-08-0810-Q
Q1 20222021-03-310.002022-05-1610-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.